Oral edaravone for patients with amyotrophic lateral sclerosis (ALS) is safe through a total of 144 weeks with no new safety signals observed. Among patients with amyotrophic lateral sclerosis (ALS), ...
Mitsubishi Tanabe Pharma filed a patent infringement lawsuit against Cipla on Oct. 16 in New Jersey District Court over their attempt to market a generic version of the ALS treatment Radicava ORS. The ...
IV edaravone-treated patient had longer disease progression milestone-free time for all 6 milestones compared with control. Treatment with intravenous (IV) edaravone was associated with fewer reported ...
JERSEY CITY, N.J., Jan. 29, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of a retrospective analysis of real-world data in the Journal of ...
Amyotrophic lateral sclerosis (ALS) is a devastating neurological disorder of unknown cause, in which motor nerve cells of the brain and spinal cord that transmit signals to muscles progressively ...
Scientists at St. Jude Children’s Research Hospital used positron emission tomography (PET) with edaravone, a drug used to treat ALS, to detect oxidative stress Positron emission tomography (PET) is a ...
Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results